THE ROLE OF STRUCTURAL SENSITIVITY ANALYSIS IN THE MODELLING OF COST-EFFECTIVENESS (COST-UTILITY) IN PARKINSON'S DISEASE IN THE UNITED STATES AND UNITED KINGDOM

被引：0
|
作者：
Ratcliffe, A. E. [1 ]
机构：
[1] PHMR Associates, London, England
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 04期
关键词：
D O I：
10.1016/j.jval.2012.03.784
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A145 / A145
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of pramipexole in Parkinson's disease in the United States
    Hoerger, TJ
    Bala, MV
    Rowland, C
    Greer, M
    Holloway, R
    [J]. NEUROLOGY, 1998, 50 (04) : A298 - A299
  • [2] Cost-Effectiveness and Cost-Utility of Early Levodopa in Parkinson's Disease
    Verschuur, Constant V. M.
    Suwijn, Sven R.
    de Haan, Rob J.
    Boel, Judith A.
    Post, Bart
    Bloem, Bas R.
    van Hilten, Johannes J.
    van Laar, Teus
    Tissingh, Gerrit
    Munts, Alexander
    Dijkgraaf, Marcel G. W.
    de Bie, Rob M. A.
    [J]. JOURNAL OF PARKINSONS DISEASE, 2022, 12 (07) : 2171 - 2178
  • [3] TREATMENT OF ADVANCED PARKINSON'S DISEASE IN THE UNITED STATES: A COST-UTILITY MODEL
    Tarrants, M. L.
    Groenendaal, H.
    Armand, C.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A370 - A370
  • [4] Treatment of advanced Parkinson's disease in the United States: a cost-utility model
    Tarrants, M.
    Groenendaal, H.
    Armand, C.
    [J]. PARKINSONISM & RELATED DISORDERS, 2009, 15 : S135 - S136
  • [5] Treatment of Advanced Parkinson's Disease in the United States A Cost-Utility Model
    Groenendaal, Huybert
    Tarrants, Marcy L.
    Armand, Christophe
    [J]. CLINICAL DRUG INVESTIGATION, 2010, 30 (11) : 789 - 798
  • [6] Influenza treatment with neuraminidase inhibitors: Cost-effectiveness and cost-utility in healthy adults in the United Kingdom
    Sander B.
    Gyldmark M.
    Hayden F.G.
    Morris J.
    Mueller E.
    Bergemann R.
    [J]. The European Journal of Health Economics, 2005, 6 (3) : 244 - 252
  • [7] The cost-effectiveness (cost-utility) of eprosartan in hypertensive patients with cerebrovascular disease in Belgium, Germany, Spain, United Kingdom, and Sweden
    Schwander, B.
    Lindgren, P.
    Gradl, B.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A237 - A238
  • [8] Cost-effectiveness of treatment with entacapone for patients with Parkinson's disease in the United States
    Palmer, C
    Nuijten, M
    Schmier, J
    Subedi, P
    Snyder, E
    [J]. ANNALS OF NEUROLOGY, 2000, 48 (03) : 496 - 496
  • [9] COST-UTILITY OF DEEP BRAIN STIMULATION FOR THE TREATMENT OF ADVANCED PARKINSON'S DISEASE IN THE UNITED STATES
    Pietzsch, J. B.
    Garner, A. M.
    Marks, W. J.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A43 - A43
  • [10] Cost-Effectiveness of Deep Brain Stimulation for Advanced Parkinson's Disease in the United States
    Pietzsch, Jan B.
    Garner, Abigail M.
    Marks, William J., Jr.
    [J]. NEUROMODULATION, 2016, 19 (07): : 689 - 697
12345